Skip to main content
SpringerLink
Log in

Patient-Clinician Choice in Palliation of Metastatic Prostate Cancer

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Palliation of patients with metastatic prostate cancer is based primarily on offering a form of androgen ablation. Each therapeutic modality has advantages and disadvantages. The decision with regards to the chosen option relies on thorough and open discussion between the treating urologist and the patient. Quality of life issues are increasingly an integral part of the treatment choice opted for. Thus, quality of life questionnaires should be incorporated into future clinical trial assessments and end-points.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I

Similar content being viewed by others

References

  1. Bolla M, Van Poppel H. Prostate cancer: an insight into screening and local treatment. Eur J Cancer 1996; 32A: 1434–5

    Article  PubMed  CAS  Google Scholar 

  2. Haas GP. Epidemiology of early prostate cancer. In Vivo 1994; 8: 403–6

    PubMed  CAS  Google Scholar 

  3. Brawley OW. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer 1997; 80: 1857–63

    Article  PubMed  CAS  Google Scholar 

  4. Smart CR. Prostate cancer facts and fiction. J Surg Oncol 1997; 66: 223–9

    Article  PubMed  CAS  Google Scholar 

  5. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–23

    Article  CAS  Google Scholar 

  6. Huggins C, Scott WW, Hodges CV. Studies on prostate cancer. III. The effects of fever of desoxy-corticosterone and of oestrogen on clinical patients with metastatic carcinoma of the prostate. J Urol 1941; 46: 997–1006

    CAS  Google Scholar 

  7. Whitmore WF. The rationale and results of ablative surgery for prostate cancer. Cancer 1963; 16: 1119–32

    Article  PubMed  Google Scholar 

  8. Veterans Administration Cooperative Urological Research Group (VACURG). Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124: 1011–7

    Google Scholar 

  9. Medical Research Council Prostate Cancer Working Party Investigators’ Group. Immediate versus deferred treatment of advanced prostate cancer: initial results of the Medical Research Council trial. Br J Urol 1997; 79: 235–46

    Article  Google Scholar 

  10. Mackler MA. The effect of orchiectomy and various doses of stilbesterol on plasma testosterone levels in patients with carcinoma of the prostate. Invest Urol 1972; 9: 423–5

    PubMed  CAS  Google Scholar 

  11. Mellinger GT, Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: a continuing co-operative study. J Urol 1964; 91: 500–94

    Google Scholar 

  12. Leuprolide Study Group. Leuprolide versus diethylstilboesterol. N Engl J Med 1986; 311: 1251–6

    Google Scholar 

  13. Turkes OA, Peeling WB, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, Zoladex against castration; a study of the British Prostate Group. J Steroid Biochem 1987; 27: 543–9

    Article  PubMed  CAS  Google Scholar 

  14. Kaisary AV, Bowsher WG, Gillatt DA, et al. Pharmacodynamics of a long acting depot preparation of avorelin in patients with prostate cancer. J Urol 1999; 162: 2019–23

    Article  PubMed  CAS  Google Scholar 

  15. Bonzani RA, Stricker HJ, Peabody JO, et al. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 1998; 160: 2446–9

    Article  PubMed  CAS  Google Scholar 

  16. Gonzales-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, et al. Luteinising hormone-releasing hormone antagonist cetorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995; 45: 275–81

    Article  Google Scholar 

  17. Neuman F. Pharmacology and and clinical uses of cyproterone acetate. In: Furr BJA, Wakeling AE, editors. Pharmacology and clinical uses of inhibitors of hormone secretion and action. Eastbourne: Bailliere Tindall, 1987: 132–59

    Google Scholar 

  18. Paisey RB, Kadow C, Bolton C, et al. Effects of cyproterone acetate and a long acting LH-RH analogue on serum lipoproteins in patients with carcinoma of the prostate. J R Soc Med 1986; 79: 210–1

    PubMed  CAS  Google Scholar 

  19. Seed M, Godsland IF, Wynn V, et al. The effects of cyproterone acetate and ethinyl estradiol on carbohydrate metabolism. Clin Endocrinol 1984; 21: 689–99

    Article  CAS  Google Scholar 

  20. Harris AL, Cantwell BMJ. Side effects of endocrine therapies used to treat breast and prostate Cancer. Clin Oncol 1985; 4: 511–33

    Google Scholar 

  21. Ohri SK, Gaer JAR, Keane PP. Hepatocellular carcinoma and treatment with cyproterone acetate. Br J Urol 1991; 67: 213–21

    Article  PubMed  CAS  Google Scholar 

  22. Darkos PE, Gez E, Catane R. Hepatitis due to cyproterone acetate. Eur J Cancer 1992; 150: 908–13

    Google Scholar 

  23. Watanabe S, Yamasaki S, Tanae A. Three cases of hepatocellular carcinoma among cyproterone users. Lancet 1994; 334: 1567–8

    Article  Google Scholar 

  24. Committee on the Safety of Medicines. Hepatic reactions with cyproterone acetate (Cyprostat, Androcur): dose-related serious hepatic toxicity may occur with prolonged use. Curr Probl Pharmacovigil 1995; 21: 1

    Google Scholar 

  25. Schroder FH. Pure antiandrogens as monotherapy in prospective studies in prostatic carcinoma. In: Treatment of prostatic cancer: facts and controversies. New York: EORTC, Genito-Urinary Group Monograph 8 Wiley-Liss, 1990: 93–103

    Google Scholar 

  26. Dijkman GA, Jankegt RA, De Reijki TM, et al. Long term efficacy and safety on nilutamide plus castration in advanced prostate cancer and the significance of early prostate specific antigen normalisation. J Urol 1997; 158: 160–3

    Article  PubMed  CAS  Google Scholar 

  27. Kaisary AV. Antiandrogen mnotherapy in the management of advanced prostate Cancer. Eur Urol 1997; 31Suppl: 2: 14–9

    PubMed  CAS  Google Scholar 

  28. Tyrrell CJ, Kaisary AV, Iversen P, et al. A randomised comparison of Casodex (bicalutamide) 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447–56

    Article  PubMed  CAS  Google Scholar 

  29. Iversen P, Tyrrell CJ, Kaisary AV, et al. Bicalutamide monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 years follow-up. J Urol 2000 Nov; 164: 1579–82

    Article  PubMed  CAS  Google Scholar 

  30. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LH-RH agonist or orchidectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 1985; 23: 833–42

    Article  PubMed  CAS  Google Scholar 

  31. Denis L, Whelan P, Carneiro de Moura JL, et al. Gosereline acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 1993; 42: 119–30

    Article  PubMed  CAS  Google Scholar 

  32. Eisenberger M, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT. 0036). National Cancer Institute Intergroup Study 0036. Semin Oncol 1994; 21: 613–9

    PubMed  CAS  Google Scholar 

  33. Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi Carcinoma. Cancer Res 1990; 50: 2275–82

    PubMed  CAS  Google Scholar 

  34. Foulds L. Neoplastic development 1. New York: Academic Press, 1969

    Google Scholar 

  35. Noble RL. Hormonal control of growth and progression in tumours of Nb rats and a theory of action. Cancer Res 1977; 37: 82–94

    PubMed  CAS  Google Scholar 

  36. Bruchovsky N, Rennie PS, Van Doorn E. Pathological growth of androgen-sensitive tissues resulting from latent actions of steroid hormones. J Toxicol Environ Health 1978; 4: 391–8

    Article  PubMed  CAS  Google Scholar 

  37. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995; 45: 839–45

    Article  PubMed  CAS  Google Scholar 

  38. Higano CS, Ellis W, Russell K, et al. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Urology 1996; 48: 800–4

    Article  PubMed  CAS  Google Scholar 

  39. Tunn UW. Intermittent endocrine therapy of prostate cancer. Eur Urol 1996; 30Suppl. 1: 22–5

    PubMed  Google Scholar 

  40. Oliver RTD, Williams G, Paris AMI, et al. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone resistant prostate cancer. Urology 1997; 49: 79–82

    Article  PubMed  CAS  Google Scholar 

  41. Theyer G, Holub S, Durer A, et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer 1997; 75: 1515–8

    Article  PubMed  CAS  Google Scholar 

  42. Grossfeld GD, Small EJ, Carroll PR. Intermittent androgen deprivation for clinically localised prostate cancer: initial experience. Urology 1998; 51: 137–44

    Article  PubMed  CAS  Google Scholar 

  43. Crook JM, Szumacher E, Malone S, et al. Intermittent androgen suppression in the management of prostate cancer. Urology 1999; 53: 530–4

    Article  PubMed  CAS  Google Scholar 

  44. Goldenberg SL, Gleave ME, Taylor D, etal. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years follow-up. Mol Urol 1999; 3: 287–92

    PubMed  CAS  Google Scholar 

  45. Bennett CL, Chapman G, Elestin AS, et al. A comparison of perspectives on prostate cancer: analysis of utility assessments of patients and physicians. Eur Urol 1997; 32Suppl. 3: 86–8

    PubMed  Google Scholar 

  46. Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health-related quality of life in men with prostate cancer: results of the caPSURE database. J Urol 1998; 159: 1988–92

    Article  PubMed  CAS  Google Scholar 

  47. Herr HW. Quality of life in prostate cancer patients. CA Cancer J Clin 1997; 47(4): 207–17

    Article  PubMed  CAS  Google Scholar 

  48. Cella D, Jacobsen P, Orav J, et al. A brief POMS measure of distress for cancer patients. J Chronic Dis 1987; 40: 939–42

    Article  PubMed  CAS  Google Scholar 

  49. Ware JE, Sherbourne CD. The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  50. Aaronson NK, Ahmedzai S, Bergman B, et al. The EORTC QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–76

    Article  PubMed  CAS  Google Scholar 

  51. McHorney CA, Ware JE, Racjek A. The MOS 36-item short form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247–63

    Article  PubMed  CAS  Google Scholar 

  52. McHorney CA, Ware JE, Lu JF, et al. The MOS 36-item short form health survey (SF-36): III. Test of data quality, scaling assumptions and reliability across diverse patient groups. Med Care 1994; 32: 40–66

    Article  PubMed  CAS  Google Scholar 

  53. Esper P, Mo F, Chodak G, et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50(6): 920–8

    Article  PubMed  CAS  Google Scholar 

  54. Stockler M. Validation of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) as an outcome measure of clinical trials in advanced hormone-resistant prostate cancer; assessment of convergent, discriminative and predictive validity with baseline data from a randomised trial [thesis]. Toronto (ON): University of Toronto, 1996

    Google Scholar 

  55. Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: the Southwest Oncology Group experience. Statist Med 1998; 17: 641–51

    Article  CAS  Google Scholar 

  56. Rosendahl I, Kiebert GM, Curran D, et al. Quality-Adjusted Survival (Q-TwiST) Analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. Prostate 1999; 38(2): 100–9

    Article  PubMed  CAS  Google Scholar 

  57. Schlenk EA, Erlen JA, Dunbar-Jacob J, et al. Health-related quality of life in chronic disorders: a comparison across studies using the MOS SF-36. Qual Life Res 1998; 7(1): 57–65

    Article  PubMed  CAS  Google Scholar 

  58. Thorpe AC, Cleary AR, Coles J, Northern Regional Prostate Audit Group, et al. Nottingham health profile measurement in the assessment of clinical outcome after prostatectomy. Br J Urol 1995; 76(4): 446–50

    Article  PubMed  CAS  Google Scholar 

  59. Popov I, Jelic S, Radosavljevic D, et al. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer: speculations about possible role of the monoamine system. Neoplasma 1997; 44(5): 308–13

    PubMed  CAS  Google Scholar 

  60. Lubeck DP, Litwin MS, Henning JM, et al. Measurement of health-related quality of life in men with prostate cancer: the CaPSURE database. Qual Life Res 1997; 6(5): 385–92

    Article  PubMed  CAS  Google Scholar 

  61. Chodak G, Sharifi R, Kassimis B, et al. Single agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 1995; 46(6): 849–55

    Article  PubMed  CAS  Google Scholar 

  62. Little JA. Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 1995; 90: 1112–21

    Article  Google Scholar 

  63. Troxel AB, Fairclough DL, Curran D, et al. Statistical analysis of quality of life data in cancer clinical trials. Stat Med 1998; 17: 653–66

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Free & University College Medical School, London, England

    Amir V. Kaisary

Authors
  1. Amir V. Kaisary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amir V. Kaisary.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaisary, A.V. Patient-Clinician Choice in Palliation of Metastatic Prostate Cancer. Drugs & Aging 17, 331–337 (2000). https://doi.org/10.2165/00002512-200017050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200017050-00001

Keywords

Search

Navigation